Maisense

Zhubei City, Taiwan

AI / ML Cardiovascular Disease Neurology

Maisense is an innovative startup working in non-invasive medical cardiovascular monitoring for personal use, combined with artificial intelligence software for stroke prevention including AFib/arrhythmia/artery stiffness detection for professional physician use. Maisense’s team includes experts in medical and engineering in Taiwan as well as the product design in Switzerland. Founded in 2012, Maisense was granted the award for "Best Investment Potential" by Taiwan’s Ministry of Economic Affairs. Maisense’s Freescan is the world first cuffless blood pressure monitor measuring directly from wrist pulse. The name "Maisense" was derived from the word “Mai” in Chinese (pulse) which is an important bio-signal for both modern medicine and traditional Chinese medicine. Maisense’s Freescan has received EC CE medical certification. It has been honored with the 2015 National Innovation Award in Taiwan, as well as ranking second among the Top 10 Innovative Health Products at the Arab Health 2016 fair in Dubai. In 2017, it has received the “Taiwan top 10 coolest innovative startups award” from the Ministry of Science and Tech in Taiwan.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Maisense on @MedStartr Today #CardiovascularDisease #StrokeCerebrovascularDisease #Arrhythmias #AtrialFibrillation #AIML #Neurology #MedMo #MedStartrVentures

https://www.medstartr.ai/s/MgFazY9A08Q

Get Involved in Maisense

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2012
Website: www.maisense.com

Disease Areas

Cardiovascular Disease Stroke & Cerebrovascular Disease Arrhythmias Atrial Fibrillation

Technologies

Non-Invasive DiagnosticsAI/Machine LearningDiagnostic DevicesPredictive Analytics

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Maisense?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.